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Abstract
Background: Praziquantel treatment of schistosomiasis during pregnancy was only recommended
in 2002; hence the effects of treatment during pregnancy are not fully known. We have therefore
evaluated the effects on infection intensity and the immunological effects of praziquantel treatment
against Schistosoma mansoni during pregnancy, compared with treatment after delivery.
Methods: A nested cohort of 387 Schistosoma mansoni infected women was recruited within a
larger trial of de-worming during pregnancy. Women were randomised to receive praziquantel or
placebo during pregnancy. All women were treated after delivery. Infection intensity after
treatment was assessed by a single Kato-Katz examination of stool samples with duplicate slides
and categorised as undetected, light (1–99 eggs per gram (epg)), moderate (100–399 epg) or heavy
(≥400 epg). Antibodies against S. mansoni worm and egg antigens were measured by ELISA. Results
were compared between women first treated during pregnancy and women first treated after
delivery.
Results: At enrolment, 252 (65.1%) of the women had light infection (median (IQR) epg: 35 (11,
59)), 75 (19.3%) moderate (median (IQR) epg: 179(131, 227)) and 60 (15.5%) had heavy infection
(median (IQR) epg: 749 (521, 1169)) with S. mansoni. At six weeks after praziquantel treatment
during pregnancy S. mansoni infection was not detectable in 81.9% of the women and prevalence
and intensity had decreased to 11.8% light, 4.7% moderate and 1.6% heavy a similar reduction when
compared with those first treated after delivery (undetected (88.5%), light (10.6%), moderate
(0.9%) and heavy (0%), p = 0.16). Parasite specific antibody levels were lower during pregnancy than
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after delivery. Praziquantel treatment during pregnancy boosted anti-worm IgG isotypes and to a
lesser extent IgE, but these boosts were less pronounced than in women whose treatment was
delayed until after delivery. Praziquantel had limited effects on antibodies against egg antigens.
Conclusion:  S mansoni antigen-specific antibody levels and praziquantel-induced boosts in
antibody levels were broadly suppressed during pregnancy, but this was not associated with major
reduction in the efficacy of praziquantel. Long-term implications of these findings in relation to
resistance to re-infection remain to be explored.
Trial registration: International Standard Randomised Controlled Trial Number for the current
study: ISRCTN32849447 http://www.controlled-trials.com/ISRCTN32849447/elliott
Background
Praziquantel treatment of human schistosomiasis during
pregnancy and lactation was avoided [1] from the time it
became available, in 1979, until an informal consultation
by the World Health Organisation in 2002. It was then
recommended that pregnant and lactating women with
schistosomiasis should be treated [2,3]. This recommen-
dation was based on animal studies, as well as case reports
of inadvertent or necessary treatment of pregnant women,
which showed no evidence of adverse effects. However,
since the benefits and risks of treatment during pregnancy
had not been studied, a WHO scientific working group in
2005 called for randomised, placebo-controlled trials of
treatment during pregnancy for all species of human
schistosomes in both low and high transmission areas [4].
We here report findings from the first such trial (Elliott et
al., 2007). In particular, we describe the results of a sub-
study designed to examine the immunological effects of
treating  Schistosoma mansoni with praziquantel during
pregnancy, compared with the effects of treatment after
delivery.
Praziquantel is the drug of choice against all schistosome
infections and has shown reliable therapeutic effective-
ness. Regular treatment of populations in endemic areas
alleviates severe morbidity [5]. One factor that may influ-
ence the efficacy of praziquantel is the immune status of
the host. Studies have demonstrated that the mode of
action of praziquantel involves unique synergy with the
host immune responses: praziquantel-induced damage of
surface membranes of schistosomes [6-8] exposes the
antigens for immune attack [9,10] and, in particular, there
is evidence that the efficacy of praziquantel against S.
mansoni is to some extent dependent on antibodies [11-
14]. At the same time, praziquantel treatment of S. man-
soni causes a boost in parasite-specific antibody responses
[15] and there is evidence that some boosts in antibody
levels, particularly in immunoglobulin (Ig)E production,
may be related to resistance to re-infection [16,17]. How-
ever, immune responses are normally altered during preg-
nancy [18] to allow foetal allograft retention [19-22] and
it is therefore of concern that praziquantel treatment dur-
ing pregnancy may be less effective than treatment in non-
pregnant women. For this reason, within our study of the
effect of praziquantel during pregnancy on immune
responses to schistosome antigens, we have also exam-
ined the effects of praziquantel on the intensity of S. man-
soni  infection and have compared effects of treatment
during pregnancy with effects of treatment after delivery.
We have previously reported that schistosome antigen-
specific cytokine responses were suppressed during preg-
nancy and that boosts in cytokine responses after praziqu-
antel treatment were smaller during pregnancy than after
delivery, in a sub-group for whom data on cytokine
responses was available [23]. We here report effects of
praziquantel treatment during pregnancy on S. mansoni
intensity and on anti-schistosome antibody responses.
Methods
Study design
A nested cohort of 387 pregnant women having schisto-
somiasis mansoni was enrolled within a larger mother
and baby cohort study on "the impact of helminths on the
response to immunization and on susceptibility to infec-
tious diseases in childhood in Uganda" (ISRCTN
32849447; http://www.controlled-trials.com/
ISRCTN32849447/elliott) [24]. The study was a ran-
domised, double-blind placebo-controlled trial using
praziquantel versus placebo and albendazole versus pla-
cebo during pregnancy in a 2 × 2 factorial design. Details
of the larger cohort and nested cohort have been
described [23,24]. Briefly: consenting mothers gave blood
for investigations including malaria parasitology, HIV
serology and immunological assays, and were asked to
provide stool samples for examination for helminth ova.
After submission of the first stool sample, they were ran-
domised to receive a single dose of either praziquantel (40
mg/kg), or placebo and albendazole (400 mg) or placebo.
At six weeks after delivery all mothers received praziquan-
tel and albendazole treatment. Follow-up samples were
obtained at six weeks post-enrolment (while still preg-
nant), six weeks after delivery (before post-delivery treat-
ment) and twelve weeks after delivery (six weeks after
post-delivery treatment). Figure one is a schematic presen-BMC Infectious Diseases 2009, 9:32 http://www.biomedcentral.com/1471-2334/9/32
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tation of the follow-up time points, the respective inter-
ventions, and samples collected.
Recruitment of the larger cohort was between April 2003
and November 2005, but recruitment to the nested
cohort, which constituted women who had S. mansoni ova
in stool, and which included additional, six-week post-
treatment follow up visits, began in November 2003.
Ethical consideration
Informed consent was obtained from each participant to
enrol in the study and provide samples as described previ-
ously [24]. Ethical clearance for the study was obtained
from the Science and Ethics Committee of Uganda Virus
Research Institute – Ministry of Health, the Uganda
National Council for Science and Technology and the
London School of Hygiene and Tropical Medicine.
Parasitological diagnosis
A single stool sample per individual was examined for S.
mansoni  ova and other helminth ova including hook-
worm by duplicate Kato-Katz thick smears [25] at respec-
tive time points. S. mansoni infection intensity was
expressed in eggs per gram (epg) of stool and categorised
as light (1–99 epg), moderate (100–399 epg) or heavy
(≥400 epg).
Parasite antigens
Antigen extracts of S. mansoni adult worm (SWA) and egg
(SEA) were prepared as previously described [10,26].
Assay of antibodies against schistosome
Immunoglobulins (Ig) G1, G2, G3, G4, E and M against
SWA and IgG1, IgG2, IgG3, IgG4 and IgE against SEA were
measured in the plasma of the subjects in duplicates per
sample using an ELISA method as described elsewhere
[27,28]. Briefly: flat bottom 96-well styrene microtitre -
9205 plates (Thermo Labsystems, USA) were coated 100
μl per well with SWA at 8 μg/ml or SEA at 2.4 μg/ml and
incubated overnight at 4°C. The standard positive pool
(prepared and optimised in-house at Department of
Pathology, Cambridge University) was serially diluted
and added in columns 1 and 2 of the plate and formed the
standard curve for quantification of antibodies. Bioti-
nylated mouse anti-human monoclonal antibodies used
for the detection were obtained from BD Pharmingen
(San Diego USA), except IgG3 which was obtained from
Zymed (S. San Francisco, USA). Poly-HRP-streptavidin
conjugate (Sanquin, Netherlands) was added at 1/4000
dilution. The plates were developed with OPD substrate
and the reaction stopped by addition of 25 μl per well of
2 M sulphuric acid on observing the colour change. Opti-
cal densities (ODs) were recorded into a data file in Del-
taSOFT II (BioMetalics, Inc USA) micro-plate analysis
software programme and exported into Microsoft excel
program. The ODs were interpolated into absolute con-
centration using Stata 5.0 (StataCorp, USA) generated
standard curves. The sensitivity of the test was the lowest
standard concentration above which levels were detecta-
ble.
Statistical analysis
Data was entered in Microsoft Excel (Microsoft, USA) and
imported into Stata (version 9 StataCorp, USA) for statis-
tical analysis.
To assess the effect of pregnancy on the praziquantel-
induced reduction in infection intensity, a simple table
and χ2 test was used to compare infection intensity catego-
ries at six weeks post treatment between women who were
first treated during pregnancy (infection intensity at six
weeks post-enrolment among praziquantel group) and
those who were first treated at six weeks after delivery
(infection intensity at 12 weeks after delivery among the
initially placebo group).
Some antibody isotypes were detectable in less than 50%
of the individuals, so antibody data was initially analysed
as binary variables dichotomised according to whether
the antibody was detectable or not. Subsequent analyses
with the levels treated as quantitative variables were found
to be more informative and are therefore presented, with
results from both approaches consistent. Since the data
was not normally distributed, non parametric statistical
tests were used, except when comparing the boosts in anti-
body data that approached a normal distribution, when
regression analysis was applied.
The analysis of schistosome antigen-specific antibodies
had three main objectives:
1. To examine effect of pregnancy on antibody levels.
Among the placebo group, antibody levels at enrolment
and six weeks post-enrolment were compared with anti-
body levels at six weeks after delivery using Wilcoxon
signed rank test.
2. To assess the effect of praziquantel treatment during
pregnancy. First, within the group treated during preg-
nancy, antibody levels before and after praziquantel treat-
ment were compared using Wilcoxon signed rank test.
Then, levels at six weeks post-enrolment were compared
between the placebo and praziquantel groups using Wil-
coxon rank sum (Mann-Whitney) test.
3. To examine the influence of pregnancy on the praziqu-
antel-induced boost in antibody levels at six weeks post-
treatment. Initially the influence of infection intensity at
enrolment and pre-treatment antibody levels on the boost
in the antibody levels were explored using spearman's cor-BMC Infectious Diseases 2009, 9:32 http://www.biomedcentral.com/1471-2334/9/32
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relation analysis. The change (boost) in antibody levels
during pregnancy among women first treated during preg-
nancy was compared with the change after delivery
among women first treated after delivery using linear
regression based on log10(antibody concentration+1).
Results
Between November 2003 and November 2005, 2208
women were recruited to the larger cohort of whom 387
(17.5%) had stool samples positive for Schistosoma man-
soni; of these 186 women received praziquantel and 201
women received placebo. Due to some participants miss-
ing scheduled appointments or insufficient amounts of
plasma samples to repeat failed antibody assays the num-
bers analysed for particular time points varied (figure 1).
Characteristics of the women at enrolment, including
intensity of schistosome infection, levels of antibodies
against schistosome antigens and prevalence of co-infec-
tions such as hookworm, P. falciparum and HIV, were sim-
ilar among the praziquantel and placebo groups
(additional file 1). Except for S. mansoni infection inten-
sity, none of these factors was associated with schistosome
antigen-specific antibody levels at enrolment (data not
shown). There were positive correlations between S. man-
soni infection intensity and levels of IgG1 (p < 0.001),
IgG2 (p = 0.01), IgG4 (p < 0.001) and IgE (p < 0.001)
against SWA and IgG4 against SEA while there were nega-
tive correlations between S. mansoni infection intensity
and levels of IgG1 (p = 0.005) IgG2 (p < 0.001) and IgG3
(p = 0.005) against SEA.
The effect of praziquantel on S. mansoni infection 
intensity was similar when given during pregnancy or after 
delivery
Among women randomised to praziquantel during preg-
nancy, 104/127 (81.9%) were negative for Schistosoma
mansoni at six weeks post-treatment while 11.8%, 4.7%
and 1.6% still had light, moderate and heavy infection
respectively. In the placebo group who were later treated
after delivery, 100/113 (88.5%) were negative while
10.6% and 0.9% still had light and moderate infection
respectively at six weeks post-treatment, while none had
heavy infection. Thus although the residual intensity was
slightly higher in the group treated during pregnancy, this
effect was small (p = 0.16). Further, there was no evidence
of an effect of gestational age at the time of treatment
among those treated during pregnancy (data not shown).
Albendazole did not influence the effects of praziquantel
treatment against S. mansoni nor did praziquantel influ-
ence the effects of albendazole against hookworm (data
not shown).
Levels of antibodies against SWA and SEA are reduced 
during pregnancy
Among the placebo group, levels of antibodies against
SWA (figure 2A) and SEA (figures 3A), at enrolment and
six weeks post-enrolment during pregnancy were consist-
ently lower than at six weeks after delivery; and this effect
was strong at enrolment for IgG1 (p < 0.001), IgG2 (p =
0.018), IgG4 (p = 0.002) and IgE (p < 0.001) against SWA,
and for IgG1 (p = 0.014) and IgG4 (p = 0.032) against SEA
and at six weeks post-enrolment for IgG1 (p < 0.001),
IgG2 (p = 0.005), IgG3 (p = 0.012), IgG4 (p = 0.001) and
IgE (p = 0.018) against SWA, and IgG1 (p = 0.001), IgG3
(p = 0.009) and IgG4 (p = 0.008) against SEA.
Praziquantel treatment during pregnancy causes boosts in 
levels of antibodies against SWA as well as IgG3 and IgE 
against SEA
Among the women who received praziquantel at enrol-
ment, there was a significant boost in levels of IgG1 (p <
0.001), IgG2 (p < 0.001), IgG3 (p = 0.011) and IgG4 (p <
0.001) against SWA at six weeks post-treatment (figure
2B). When antibody levels at six weeks post-enrolment
were compared between the placebo and the praziquantel
groups, the levels of antibodies against SWA were higher
in the praziquantel group than in the placebo group (p <
0.001 for IgG1-3, p = 0.034 for IgG4, p = 0.049 for IgE and
p = 0.013 for IgM). Levels of IgE against SWA did not show
significant boost at six weeks post-treatment, but at six
weeks after delivery IgE levels were significantly higher
than pre-treatment (p < 0.001) and six weeks post-treat-
ment (p = 0.006), and the level among women treated
during pregnancy was again higher than among those
who received placebo (p = 0.018). IgG subtypes and IgM
showed no further increase after delivery.
In contrast, boosts in antibodies against SEA were only
seen for IgG3 (p-value= 0.02) and IgE (p-value = 0.043),
with levels at six weeks post-treatment higher than pre-
treatment levels (figure 3B). When antibody levels at six
weeks post-enrolment were compared between the pla-
cebo and praziquantel groups, levels of IgG2 (p = 0.006),
IgG3 and IgE (p < 0.001) against SEA were higher among
the praziquantel group than the placebo group. On the
other hand, the level of IgG4 against SEA showed signifi-
cant decline between enrolment and six weeks post-treat-
ment (p = 0.02) and at six weeks post-enrolment the levels
were not significantly different between the placebo and
praziquantel group.
Pregnancy causes suppression of praziquantel induced-
boost in levels of some antibodies against SWA and SEA
Antibody levels in the group randomised to placebo and
who received initial praziquantel treatment at six weeks
after delivery were examined at 6 weeks post-treatment to
assess the effect of treating non-pregnant women (figures
2A and 3A). Significant boosts in antibodies against SWA
(p < 0.001 for IgG1-4, and IgM) as well as IgG2 (p <
0.001) and IgE (p = 0.006) against SEA were observed at
six weeks after post-delivery treatment. As observed with
treatment during pregnancy, levels of IgG4 against SEA (pBMC Infectious Diseases 2009, 9:32 http://www.biomedcentral.com/1471-2334/9/32
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Flow diagram showing the scheduled time points of the study and samples assessed at the respective time points Figure 1
Flow diagram showing the scheduled time points of the study and samples assessed at the respective time 
points. *Women who missed attending or providing samples at some time points were allowed to participate at subsequent 
follow-up time points.
Six weeks after delivery 
x Stool assessed for S.
mansoni eggs (n=169*) 
x Plasma assessed for 
antibody levels (n=108) 
xReceived praziquantel and 
albendazole
12 weeks after delivery 
x Stool assessed for S. mansoni
eggs (n=113) 
x Plasma assessed for antibody
levels (n=89) 
12 weeks after delivery 
x Stool assessed for S. mansoni
eggs (n=111) 
x Plasma assessed for antibody
levels (n=105)
Six weeks after delivery 
x Stool assessed for S. mansoni
eggs (n=165*)
x Plasma assessed for antibody 
levels (n=105) 
x Received praziquantel and 
albendazole 
Received praziquantel 
n=186
Received placebo 
n=201
Delivery 
Six weeks post-enrolment 
x Stool assessed for S. mansoni
eggs (n=127) 
x Plasma assessed for antibody
levels (n=124) 
Delivery 
Nested cohort; enrolled for the 
schistosome immunology study 
n=387
Six weeks post-enrolment 
x Stool assessed for S.
mansoni egg (n=131) 
x Plasma assessed for 
antibody levels (n=125) BMC Infectious Diseases 2009, 9:32 http://www.biomedcentral.com/1471-2334/9/32
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Plasma levels of antibodies against S. mansoni adult worm antigen (SWA) and effect of praziquantel treatment during pregnancy  or after delivery on the antibody levels Figure 2
Plasma levels of antibodies against S. mansoni adult worm antigen (SWA) and effect of praziquantel treatment 
during pregnancy or after delivery on the antibody levels. The y-axis shows log10 (antibody concentrations (pg/ml)+1). 
The x-axis shows time points: enrolment (Enrol), 6 weeks post-enrolment (6 wks PE), 6 weeks after delivery (6 wksAD) and 
12 weeks after delivery (12 wks AD). The arrows indicate the intervention time points when the women were given either pla-
cebo (black) or praziquantel treatment (red). The box plots in column A are for participants who received placebo at enrol-
ment during pregnancy and received praziquantel treatment for the first time six weeks after delivery. The box plots in column 
B are for participants who received praziquantel treatment during pregnancy. P values are given for the comparison in boost in 
antibody levels for praziquantel given for the first time during pregnancy vs after delivery, adjusted for pre-treatment antibody 
levels, S. mansoni infection intensity at enrolment and concurrent albendazole therapy. P values for other comparisons are 
given in the text.
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= 0.007) significantly declined following post-delivery
praziquantel treatment.
Comparing post-treatment antibody levels by timing of
treatment showed that the boosts in antibody levels were
generally lower for treatment during pregnancy than for
treatment after delivery (additional file 2). As well as
absolute antibody levels, boosts in antibody levels against
SWA tended to show a positive association with infection
intensity at enrolment (data not shown). After adjusting
for the pre-treatment antibody levels, infection intensity
at enrolment and albendazole treatment, the post-treat-
ment boosts remained lower for the women first treated
during pregnancy than those first treated after delivery,
particularly significant for IgG3, IgG4 and IgM against
SWA and for IgG1 and IgG2 against SEA (additional file
2).
Discussion
This study suggests that praziquantel treatment against S.
mansoni during pregnancy has similar efficacy as praziqu-
antel treatment in non-pregnant women, despite the pres-
ence of lower levels of anti-schistosome antibodies and
tendency to reduced boosting of both antibody and
cytokine responses observed during pregnancy.
In assessing effects on S. mansoni infection intensity, the
chief limitation of this study was the use of a single stool
sample to determine prevalence and intensity of S. man-
soni after treatment. A single stool sample has low sensi-
tivity in detection of helminth infections [29-31], hence
the prevalence will have been underestimated and esti-
mates of intensity will have been imprecise. However,
since comparisons were made between randomised
groups, these limitations are likely to have applied simi-
larly at follow up in both groups; the proportion appar-
ently "cured" will have been exaggerated in both groups,
but the comparison remains valid, suggesting little differ-
ence in the effect of treatment during pregnancy or after
delivery.
In this study, alterations in the levels of schistosome anti-
gen-specific antibodies during pregnancy, as well as the
effect of praziquantel treatment during pregnancy on the
antibody levels, were elucidated. Levels of IgG1, IgG2,
IgG3, IgG4 and IgE against SWA and SEA, were generally
low during pregnancy. These findings accord those of
Novato-Silva and colleagues [32] showing that antibody
levels against adult schistosome worm antigens declined
with progression of pregnancy. These observations are
contrary to other reports on antibodies to non-schisto-
some antigens showing that humoral immune responses
are not affected by progression of pregnancy [19,33].
There is normally an increase in plasma and blood vol-
ume during pregnancy [34] which is apparent at six weeks,
and is maximum (40–50%) between 32–36 weeks, of
pregnancy [34,35]. Although this dilution effect of
increased blood volume of pregnancy was not examined
in our study, it could potentially explain the low antibody
levels during pregnancy rather than a decline in the anti-
body responses per se.
Praziquantel treatment during pregnancy caused a boost
in antibody levels against SWA and to a limited extent
SEA; although a significant drop in levels of IgG4 against
SEA was observed. These boosts in antibodies at six weeks
post-treatment were consistent with those observed at five
weeks post-treatment [36], three months post-treatment
[37] and at six months post-treatment [27] among S. man-
soni infected non-pregnant individuals in endemic areas.
Similar increases in antibodies were recently reported fol-
lowing treatment among non-pregnant adults from a new
focus of S. mansoni infection [38]. The decline in the level
of IgG4 against SEA following praziquantel treatment was
also consistent with findings reported among non-preg-
nant individuals [37,39]. The boost in IgE against SWA
was less marked than for other antibodies against SWA. It
is possible that six weeks after treatment could have been
too short a follow-up time to observe a significant boost
in levels of IgE against SWA. This was consistent with
other studies where post-treatment levels of IgE against
SWA were not significantly boosted at three weeks [26]
and five weeks [36], following treatment, suggesting that
this particular isotype remains relatively stable over time
among adults in S. mansoni endemic areas.
Although boosts in schistosome antigen-specific antibody
response were observed during pregnancy, these were gen-
erally lower, and post-treatment antibody levels were
lower, compared with treatment after delivery. However,
in spite of this, the data did not show evidence that preg-
nancy and having lower boosts in schistosome antigen
specific antibody isotypes had any significant impact on
the efficacy of praziquantel treatment against S. mansoni.
Suppression of the boosts in antibodies during pregnancy
may, however, have effects on resistance to reinfection.
Due to limited follow-up time and since all the women
received praziquantel treatment after delivery, the impact
of treatment during pregnancy on susceptibility to reinfec-
tion after treatment was not explored. Therefore, further
studies might be necessary to examine the long-term
implications of the suppression of boosts in some of the
antibody isotypes following treatment during pregnancy.
Conclusion
This study, the first to examine the impact of praziquantel
treatment during pregnancy, has shown that S mansoni
antigen-specific antibody levels and praziquantel-induced
boosts in the antibody levels are broadly low during preg-
nancy, but that this is not associated with any majorBMC Infectious Diseases 2009, 9:32 http://www.biomedcentral.com/1471-2334/9/32
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Plasma levels of antibodies against S. mansoni egg antigen (SEA) and effect of praziquantel treatment during pregnancy or after  delivery on the antibody levels Figure 3
Plasma levels of antibodies against S. mansoni egg antigen (SEA) and effect of praziquantel treatment during 
pregnancy or after delivery on the antibody levels. The y-axis shows log10 (antibody concentrations (pg/ml)+1). The x-
axis shows time points: enrolment (Enrol), 6 weeks post-enrolment (6 wks PE), 6 weeks after delivery (6 wksAD) and 12 
weeks after delivery (12 wks AD). The arrows indicate the intervention time points when the women were given either pla-
cebo (black) or praziquantel treatment (red). The box plots in column A are for participants who received placebo at enrol-
ment during pregnancy and received praziquantel treatment for the first time six weeks after delivery. The box plots in column 
B are for participants who received praziquantel treatment during pregnancy. P values are given for the comparison in boost in 
antibody levels for praziquantel given for the first time during pregnancy vs after delivery, adjusted for pre-treatment antibody 
levels, S. mansoni infection intensity at enrolment and concurrent albendazole therapy. P values for other comparisons are 
given in the text.
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reduction in the efficacy of praziquantel in the treatment
of light to moderate intensity S. mansoni infections: a
result that is reassuring from a public health perspective.
Effects of pregnancy on the response to praziquantel
among populations with higher S. mansoni infection
intensities, and among women with S. haematobium or S.
japonicum, and the long-term implications of these find-
ings, particularly in relation to resistance to re-infection,
remain to be explored.
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